Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung condition characterized by chronic respiratory symptoms due to abnormalities of the airways and/or alveoli that cause persistent, often progressive, airflow obstruction. In this webinar recording, Dr. Chan, Ka-Pang Ken from The Chinese University of Hong Kong, explained the updates presented in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) report (i.e.version 2023) and the rationale for selecting suitable treatments. 

There is a new classification system for COPD, combining groups C and D from previous years into the newly created group E. Recommendations were also updated in each corresponding category of patients. Dual long-acting bronchodilator combinations LAMA/LABA like tiotropium/olodaterol are now recommended in most patients with preference to products that have been formulated into a single device. The report also highlighted the choice of delivery device as an important consideration in treatment selection. Dr. Chan reminded us that the role of an healthcare professional is to pick the most suitable inhaler for their patients and that proper education on inhaler techniques are important to improve compliance and adherence.